ProQuest www.csa.com
 
About CSA Products Support & Training News and Events Contact Us
 
RefWorks
  
Discovery Guides Areas
>
>
>
>
>
 
  
e-Journal

 

Direct-to-Consumer Advertising of Pharmaceuticals
(Released March 2008)

 
  by Amy Shaw  

Review

Key Citations

Resources

Glossary

Editor
 
Conclusion

Contents

DTC advertising has become a major marketing phenomenon in the American health care system. It has been a contentious subject among consumers, those in the medical community, and the pharmaceutical industry. The pharmaceutical companies assert that DTC advertising can help consumers become more informed about diseases and prescription drug choices. They also argue that these advertisements may make patients more likely to seek help and discuss their conditions with their doctors, thus getting the treatments they need. Furthermore, physician attitudes toward DTC advertising are changing, with more expressing positive views than in the past.

Patient advocacy groups have put a great deal of pressure on the FDA to speed the release of new drugs, some of which are found to not perform any better than older versions. The marketing of these new drugs has led to recalls of heavily advertised drugs, such as Vioxx, that were found to carry dangerous risks. PhRMA and some pharmaceutical companies, such as Bristol-Myers Squib, have reacted by announcing a voluntary moratorium on DTC advertising for new drugs.

In addition to issues regarding the advertising of new DTC drugs, critics argue that drug companies should more clearly indicate who may be at risk of the disease being treated (Frosch et al, 2007) and show fair balance in stating a drug's risks and benefits of a drug. They furthermore assert that drug companies should advise the consumers that other treatment options may be available.

The debate continues while DTC advertising grows as a marketing phenomenon in the American health care system.

© 2008, ProQuest LLC. All rights reserved.

List of Visuals

References

  1. Advertising/Labeling Definitions. The CDER Handbook. http://www.fda.gov/cder/handbook/adverdef.htm

  2. Bradford, D.W., and Kleit, A.N. (2006). "Evaluating the Welfare Effects of Drug Advertising." Regulation 29(1), pp. 58-62.

  3. Chantix TM Homepage. (2008). Pfizer. http://www.chantix.com/content/Chantix_Branded_Homepage.
    jsp?setShowOn=../content/Chantix_Branded_Homepage.jsp&set
    ShowHighlightOn=../content/Chantix_Branded_Homepage.jsp

  4. Choi, S.M. and Lee,W. (2007). Understanding the impact of direct-to-consumer (DTC) pharmaceutical advertising on patient-physician interactions: Adding the web to the mix. Journal of Advertising., 36(3) pp. 137-149.

  5. Conrad, P., and Leiter, V. (2004). Medicalization, Markets and Consumers. Journal of health and social behavior 45(Suppl) pp. 158-176.

  6. Croghan, T.W. and Pittman, P. (2004). The Medicine Cabinet: What's in it, Why, and can we Change the Contents? Health affairs (Project Hope) 23(1), pp. 23-33.

  7. Cunningham, D.J. and Iyer, R. (2005). Does DTC Mean "Direct to Court"." Journal of Consumer Marketing 22(7), pp. 412-420.

  8. CR Report: New Oral Diabetes Medicines No More Effective, Safe than Lower-Cost, Older Drugs; Metformin Best First-Step Choice for Most People with Diabetes. (2007). PR Newswire.

  9. Direct-to-Consumer (DTC) Marketing for U.S. Prescription Drugs Moves Online, Cegedim Dendrite Survey Says. (2007). Business Wire.

  10. Donohue, J., Cevasco, M. and Rosenthal M.B. (2007). A Decade of Direct-to-Consumer Advertising of Prescription Drugs. The New England Journal of Medicine, 357(7), 673-681.

  11. DTC Prescription Drug Advertising. (2007, Oct.) American Advertising Federation. http://www.aaf.org/default.asp?id=248

  12. FDA Budget Summary. (2008, Feb) U.S. Food and Drug Administration. http://www.fda.gov/oc/oms/ofm/budget/documentation.htm

  13. Finlayson, G. and Mullner, R. (2005) Direct-to-Consumer Advertising of Prescription Drugs: Help Or Hindrance to the Public's Health? Journal of Consumer Marketing 22(7), pp. 429-431.

  14. Freudenheim, M. (2007, Jan 22). Showdown Looms in Congress over Drug Advertising on TV. New York Times, pp. C.1.

  15. Frosch, Dominick L., Krueger, P.M., Hornik, R.C., Cronholm, P.F., Barg, F.K. (2007, Jan-Feb). Creating demand for prescription drugs: A content analysis of television direct-to-consumer advertising. Annals of Family Medicine. 5(1) pp. 6-13.

  16. Gagnon, M. A. and Lexchin, J. (2008, Jan) The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. PloS Medicine. http://medicine.plosjournals.org/perlserv/?request=get-
    document&doi=10.1371%2Fjournal.pmed.0050001

  17. Healy, M. (2007, Aug 6). The Payoff; In Short, Marketing Works By Targeting Consumers and Doctors--Directly and Indirectly--Drug Makers Are Driving Sales. Why Mess with Success? Los Angeles Times, pp. F.6.

  18. Heinrichs, A. M. (2007, Aug. 16) Pitt Prof Claims Government Surfs Past TV Drug Ads.

  19. The Henry J. Kaiser Family Foundation. Impact of Direct-to-Consumer Advertising on Prescription Drug Spending. (2003, June).
    http://www.kff.org/rxdrugs/upload/Impact-of-Direct-to-Consumer-
    Advertising-on-Prescription-Drug-Spending-Summary-of-Findings.pdf

  20. Huh, J., Langteau, R. (2007). Presumed influence of DTC prescription drug advertising: Do experts and novices think differently? Communication Research. 34(1) pp. 25-52.

  21. H.R. 3580, (2007, Jan 4) U.S. Food and Drug Administration. http://www.fda.gov/oc/initiatives/HR3580.pdf

  22. Jaramillo, D.L. (2006). Pills gone wild: Medium specificity and the regulation of prescription drug advertising on television. Television & New Media. 7(3) pp. 261-281.

  23. Kritz, F. L. (2008, Feb 11). MEDICINE; Promises, Promises; As Efforts to Rein in TV Drug Ads Stumble, Experts Worry That Too Many Go Unchecked and Risks Are Underplayed. Los Angeles Times, pp. F.3.

  24. Lazarus, D. (2008, Feb 6). Ads Spur Urge for Drugs. Los Angeles Times, pp. C.1.

  25. Metzl, Jonathan M. (2007). If Direct-to-Consumer Advertisements Come to Europe: Lessons from the USA. Lancet 369(9562), pp. 704-706.

  26. Miller, J.D. (2007). "Study Affirms PhRMA's Influence on Physicians." Journal of the National Cancer Institute 99(15), pp. 1148-1150.

  27. Morris, Albert W., Jr., Sandra L. Gadson, and Valentine Burroughs. (2007). "for the Good of the Patient," Survey of the Physicians of the National Medical Association regarding Perceptions of DTC Advertising, Part II, 2006. Journal of the National Medical Association 99(3), pp. 287-293.

  28. Murray, E., Lo, B., Pollack, L., Donelan, K. and Lee, K. Direct-to-Consumer Advertising: Physicians' Views of its Effects on Quality of Care and the Doctor-Patient Relationship. (2003). The Journal of the American Board of Family Practice / American Board of Family Practice 16(6), pp. 513-524.

  29. NEJM Direct-to-Consumer Ad Study Shows Drug Industry Incapable of Self-Regulation. (2007, Aug. 16). AIDS Healthcare Foundation. http://www.aidshealth.org/index.php?option=com_
    content&task=view&id=1130&Itemid=193

  30. PhRMA Guiding Principles: Direct to Consumer Advertisements about Prescription Medicines. (2005, Nov.) PhRMA. http://www.phrma.org/files/DTCGuidingprinciples.pdf

  31. Rados, C. (2004). "Truth in Advertising: Rx Drug Ads Come of Age." FDA consumer 38(4), pp. 20-27.

  32. Roan, S. (2007, Dec 31). Drug's Delay Mobilizes Prostate Patients to Activism. Los Angeles Times, pp. F.1.

  33. Robinson, A., Hohmann, K., Rifkin J., Topp, D., Gilroy, C., Pickard, J., and Anderson, R. (2004). "Direct-to-Consumer Pharmaceutical Advertising: Physician and Public Opinion and Potential Effects on the Physician-Patient Relationship." Archives of Internal Medicine 164(4), pp.427-432.

  34. Sheehan, K. (2007). Direct-to-consumer (DTC) branded drug web

  35. Spake, D.F. and Mathew, J. (2007). Consumer opinion and effectiveness of direct-to-consumer advertising. Journal of Consumer Marketing 24(5), pp. 283-292.

  36. Strattera Warning Letter. (2005) U.S. Food and Drug Administration. http://www.fda.gov/cder/warn/2005/strattera.pdf

  37. United States Government Accountability Office. (2002). Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations: report to congressional requesters.

  38. United States Government Accountability Office. (2006). Prescription Drugs: Improvements Needed in FDA's Oversight of Direct-to-Consumer pp. ii+47.

  39. Vedantam, S. (2006, Dec 1). Cost Benefits of New Schizophrenia Drugs Doubted; Older Medication, Considered Equally Effective, Can Be as Much as $600 a Month Cheaper, Study Finds. The Washington Post, pp. A.9.
Note: All webpages cited here have been downloaded in February of 2008